TARRYTOWN, N.Y.--(BUSINESS WIRE)--Siemens Healthineers will invest around $300 million in its Walpole, Mass. laboratory diagnostics manufacturing and research and development facility. The investment extends over four years and is another proof point that Siemens Healthineers invests in innovation to enable healthcare providers around the world to meet their current challenges and to excel in their respective environments. Through products and solutions designed to increase efficiency and reduce costs, Siemens Healthineers sets new trends in healthcare together with its customers – working under the motto “Engineering Success. Pioneering Healthcare. Together.”
“The expansion of the Walpole facility fits into the strategic growth plans for the company and allows us to increase our manufacturing footprint in the United States, the largest healthcare market in the world,” said Bernd Montag, Chief Executive Officer, Siemens Healthineers.“The laboratory instruments and reagents developed and manufactured at the Siemens Healthineers Walpole facility impact patients and healthcare providers across the globe.”
The Walpole facility currently employs more than 700 employees and is the main manufacturing facility for assays that run on the ADVIA® Centaur family of immunoassay instruments, and for consumables for the company's molecular and blood gas testing instruments. The facility will also manufacture assays to run on the immunoassay module of the Atellica™ Solution¹, which is currently under FDA review. R&D efforts at the site bring new tests to the diagnostics market to help physicians diagnose and treat disease.
“With a 37-year history of manufacturing products in Walpole, we saw an opportunity to leverage the local talent in the community to further our growth and expansion plans,” said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers.
The company plans to upgrade and expand its existing 500,000 sq. ft. complex. Renovations to the existing facility will begin in the coming weeks. The expansion—which will include manufacturing, warehouse, office and lab space—is set to begin in the summer. Siemens Healthineers is committed to creating at least 400 positions. The company anticipates that it may ultimately create up to as many as 700 new permanent jobs to bring the total employment at the site to between 1,300 and 1,600 by 2026. These employees will join the 46,000 Siemens Healthineers around the world who enable healthcare providers to deliver excellent patient care.
“I am proud that Siemens has chosen to grow its laboratory diagnostics unit in Massachusetts,” said Governor Charlie Baker. “The Commonwealth is pleased to continue building a pro-growth economic environment that creates more jobs for our communities, and remains focused on supporting globally competitive life sciences and advanced manufacturing. I thank Siemens Healthineers for their commitment to Massachusetts, and look forward to continuing to partner with the company to move this important economic development project forward.”
¹ Product is under FDA review. Not available for sale. Future
availability cannot be guaranteed.
² Based on data presented by RKG Associates Economic Impact Analysis
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today’s dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers. In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and profit of over €2.3 billion and has about 46,000 employees worldwide. Further information is available at www.siemens.com/healthineers.
This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens' management, of which many are beyond Siemens' control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in disclosures, in particular in the chapter Risks in the Annual Report. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.